Photodynamic therapy of gynecologic neoplasms after presensitization with hematoporphyrin derivative.
Five patients with various gynecologic neoplasms were treated with photodynamic therapy using 630-nm light delivered from an argon dye laser system following the intravenous injection of hematoporphyrin derivative (HpD). A patient with multifocal squamous cell cancer of the vagina had no evidence of disease 15 months after her first photodynamic therapy treatment. Autopsy nine months after the first treatment of another patient with multifocal invasive cancer of the vagina and parametrium showed no evidence of tumor on the surface of the vagina. Eight months after treatment of an 8 X 12 cm area of Bowen's disease of the vulva and thigh, there was no evidence of disease. Vaginal bleeding from breast cancer metastatic to the endometrium was controlled by one treatment until the patient expired five months later from her disease. Adenocarcinoma metastatic to the vaginal cuff showed partial response when vaginectomy was performed five weeks after photodynamic therapy.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D001913:Bowen's Disease / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006414:Hematoporphyrin Photoradiation; D006801:Humans; D053685:Laser Therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010778:Photochemotherapy; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000556:secondary; D014625:Vaginal Neoplasms / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy